93 related articles for article (PubMed ID: 3065203)
1. Severe hypoglycemia as a short-term side-effect of the somatostatin analog SMS 201-995 in insulin-dependent diabetes mellitus.
Navascuès I; Gil J; Pascau C; Senen D; Serrano-Rios M
Horm Metab Res; 1988 Dec; 20(12):749-50. PubMed ID: 3065203
[TBL] [Abstract][Full Text] [Related]
2. Somatostatin analog SMS 201-995 and insulin needs in insulin-dependent diabetic patients studied by means of an artificial pancreas.
Rios MS; Navascues I; Saban J; Ordoñez A; Sevilla F; Del Pozo E
J Clin Endocrinol Metab; 1986 Nov; 63(5):1071-4. PubMed ID: 2876005
[TBL] [Abstract][Full Text] [Related]
3. Somatostatin and counterregulatory hormone responses to hypoglycaemia in diabetics with and without autonomic neuropathy.
Fernandez-Castaner M; Webb S; Levy I; Rios M; Casamitjana R; Bergua M; Figuerola D; Rivera F
Diabete Metab; 1985 Apr; 11(2):81-6. PubMed ID: 2861121
[TBL] [Abstract][Full Text] [Related]
4. Effect of a long-acting somatostatin derivative SMS 201-995 (sandostatin) on glucose homeostasis in type I diabetes mellitus.
Navascues I; Gil J; Pascau C; Senén D; del Pozo E; Serrano-Ríos M
Horm Res; 1988; 29(2-3):92-4. PubMed ID: 2900205
[TBL] [Abstract][Full Text] [Related]
5. The effects of the somatostatin analogue SMS 201-995 on carbohydrate homeostasis of insulin-dependent diabetics as assessed by the artificial endocrine pancreas.
Hadjidakis DJ; Halvatsiotis PG; Ioannou YJ; Mavrokefalos PJ; Raptis SA
Diabetes Res Clin Pract; 1988 Jul; 5(2):91-8. PubMed ID: 2901329
[TBL] [Abstract][Full Text] [Related]
6. Sandostatin, a new analogue of somatostatin, reduces the metabolic changes induced by the nocturnal interruption of continuous subcutaneous insulin infusion in type 1 (insulin-dependent) diabetic patients.
Scheen AJ; Gillet J; Rosenthaler J; Guiot J; Henrivaux P; Jandrain B; Lefèbvre PJ
Diabetologia; 1989 Nov; 32(11):801-9. PubMed ID: 2687064
[TBL] [Abstract][Full Text] [Related]
7. Acute effect of the somatostatin analogue SMS-201995 on plasma glucose and triglycerides in insulin-dependent diabetic patients.
Malerbi DA; de-Camargo JW; Cesar FP; Wajchenberg BL
Braz J Med Biol Res; 1992; 25(6):593-600. PubMed ID: 1342235
[TBL] [Abstract][Full Text] [Related]
8. Long-term improvement in metabolic control of unstable type I diabetes by s.c. insulin injection patterns based on the dose profiles required by bed-side artificial beta-cell.
Bombor H; Bruns W; Ratzmann KP; Jutzi E; Albrecht G; Michaelis D; Fischer U
Exp Clin Endocrinol; 1984 Apr; 83(2):143-51. PubMed ID: 6373316
[TBL] [Abstract][Full Text] [Related]
9. Hypoglycemia after administration of somatostatin analog (SMS 201-995) in metastatic carcinoid.
Brunner JE; Kruger DF; Basha MA; Meiri E; Kaatz SS
Henry Ford Hosp Med J; 1989; 37(2):60-2. PubMed ID: 2606730
[TBL] [Abstract][Full Text] [Related]
10. Reduced postprandial hyperglycemia after subcutaneous injection of a somatostatin-analogue (SMS 201-995) in insulin-dependent diabetes mellitus.
Spinas GA; Bock A; Keller U
Diabetes Care; 1985; 8(5):429-35. PubMed ID: 2865093
[TBL] [Abstract][Full Text] [Related]
11. The bionic pancreas: novel perspectives on insulin replacement therapies.
Denecke C
Transplantation; 2015 Feb; 99(2):268-9. PubMed ID: 25651115
[No Abstract] [Full Text] [Related]
12. Nonwarning hypoglycemia in drivers with diabetes.
Haunz EA; Brosseau JD
Am Fam Physician; 1984 Oct; 30(4):189-97. PubMed ID: 6388291
[TBL] [Abstract][Full Text] [Related]
13. Improved postprandial metabolic control after subcutaneous injection of a short-acting insulin analog in IDDM of short duration with residual pancreatic beta-cell function.
Pampanelli S; Torlone E; Ialli C; Del Sindaco P; Ciofetta M; Lepore M; Bartocci L; Brunetti P; Bolli GB
Diabetes Care; 1995 Nov; 18(11):1452-9. PubMed ID: 8722069
[TBL] [Abstract][Full Text] [Related]
14. Improvement of diabetic peripheral neuropathy with the portable insulin infusion pump.
Tolaymat A; Roque JL; Russo LS
South Med J; 1982 Feb; 75(2):185-9. PubMed ID: 7036357
[TBL] [Abstract][Full Text] [Related]
15. Short-term of the artificial beta-cell (Biostator) on pancreatic glucagon response in insulin-dependent diabetic (IDDM).
Ratzmann KP; Schneider U; Besch W; Heinke P
Exp Clin Endocrinol; 1984 Jul; 84(1):91-8. PubMed ID: 6383851
[TBL] [Abstract][Full Text] [Related]
16. Somatostatin reduces posthypoglycemic insulin resistance in insulin-dependent diabetes mellitus.
Kollind M; Adamson U; Lins PE
Acta Endocrinol (Copenh); 1988 Jun; 118(2):173-8. PubMed ID: 2898855
[TBL] [Abstract][Full Text] [Related]
17. Effect of Insulin Analogs on Frequency of Non-Severe Hypoglycemia in Patients with Type 1 Diabetes Prone to Severe Hypoglycemia: Much Higher Rates Detected by Continuous Glucose Monitoring than by Self-Monitoring of Blood Glucose-The HypoAna Trial.
Agesen RM; Kristensen PL; Beck-Nielsen H; Nørgaard K; Perrild H; Jensen T; Parving HH; Thorsteinsson B; Tarnow L; Pedersen-Bjergaard U
Diabetes Technol Ther; 2018 Mar; 20(3):247-256. PubMed ID: 29565719
[TBL] [Abstract][Full Text] [Related]
18. Suicidal insulin overdose in a type 1 diabetic patient: relation of serum insulin concentrations to the duration of hypoglycemia.
Shibutani Y; Ogawa C
J Diabetes Complications; 2000; 14(1):60-2. PubMed ID: 10925068
[TBL] [Abstract][Full Text] [Related]
19. Effects of a somatostatin derivative (SMS 201-995) on postprandial hyperglycemia in insulin-dependent diabetics studied by means of a closed-loop device.
Nosari I; Lepore G; Querci F; Maglio ML; Sileo F; Pagani G
J Endocrinol Invest; 1989 Jun; 12(6):413-7. PubMed ID: 2671112
[TBL] [Abstract][Full Text] [Related]
20. [Use of the biostator for programming the insulin infusion pump Microjet-Bolus-2 in the treatment of insulin-dependent diabetes mellitus].
Sieradzki J; Szurkowska M
Pol Arch Med Wewn; 1988 May; 79(5):271-7. PubMed ID: 3078197
[No Abstract] [Full Text] [Related]
[Next] [New Search]
